Genentech Triples Lobbying Spend to $1.81M as Medicare Drug Price Negotiations Intensify
Key Insights
Genentech disclosed $1.81 million in Q2 2026 lobbying expenditures, more than triple the $378,000 spent in Q1 2026, signaling heightened engagement on drug pricing policy.
The Inflation Reduction Act's Medicare Drug Price Negotiation Program took effect January 1, 2026, with CMS now negotiating prices for 15 additional drugs for 2027 implementation.
The Midsized Biotech Alliance separately spent $230,000 in Q2 2026, arguing the Trump administration's Most Favored Nation tariff policy risks undermining American biotech innovation.
Genentech has dramatically escalated its federal lobbying efforts, disclosing $1.81 million in expenditures for the second quarter of 2026, a figure that more than triples the $378,000 the company reported in the first quarter. The surge in spending comes as the biotechnology giant navigates an increasingly complex regulatory environment shaped by the Inflation Reduction Act's Medicare Drug Price Negotiation Program, which took effect on January 1, 2026.
The company's lobbying disclosure report, filed under the Lobbying Disclosure Act, cited broad general issue areas including budget and appropriations, copyright and patent, health issues, immigration, manufacturing, medical and disease research, Medicare and Medicaid, pharmacy, taxation, and trade. Notably, the filing left the specific legislative targets field blank, limiting transparency into precisely which bills or proposals drew Genentech's attention during the quarter.
Medicare Negotiations Drive Policy Engagement
The intensified lobbying activity unfolds against the backdrop of the Inflation Reduction Act's drug pricing provisions. Prices for the first 10 drugs selected under the Medicare Drug Price Negotiation Program are now in effect, and the Centers for Medicare & Medicaid Services is actively negotiating prices for 15 additional drugs slated for 2027 implementation.
Genentech's Q2 2026 spending, while a sharp increase from the prior quarter, aligns more closely with historical patterns. The company disclosed $1.94 million in lobbying expenditures during the second quarter of the prior year, suggesting a seasonal rhythm to its advocacy efforts.
External Lobbying Firms Bolster Genentech's Reach
Beyond its in-house advocacy, Genentech retained multiple external firms to advance its policy interests. OGR (search) lobbied on the company's behalf for $60,000, focusing on public health preparedness issues in the prior quarter. Forbes Tate Partners (search) registered for $50,000 in the first quarter, covering intellectual property, patent matters, Medicare and Medicaid, 340B drug pricing, and tax-related issues.
Midsized Biotech Alliance Joins the Fray
In a parallel development, the Midsized Biotech Alliance of America (search) Inc. filed its own Q2 2026 lobbying disclosure, reporting $230,000 in federal advocacy spending. The alliance, represented by LMH Strategic Solutions (search) LLC, has focused its efforts on the Trump administration's Most Favored Nation drug pricing policy.
The MFN policy, projected to generate $529 billion in savings over 10 years by aligning U.S. drug prices with those paid by other developed nations, presents a stark choice for pharmaceutical companies. Firms that sign MFN agreements and submit onshoring plans face zero percent tariffs until January 20, 2029, while those that decline could face tariffs as high as 100 percent.
The Midsized Biotech Alliance has pushed back against this tariff ultimatum, arguing that the policy risks undermining American biotech companies that drive the majority of new breakthroughs in cancer, rare diseases, and other life-threatening conditions.
The lobbying team at LMH Strategic Solutions (search) includes founder Alanna Temme, who previously served as legislative director to former Representative Jon Porter and held roles on the House Financial Services Committee and the House Education and the Workforce Committee, along with Amy Efantis, who brings experience spanning five consecutive congresses over nearly seven years. Max Walter serves as director of government affairs and health policy for the alliance.
Limited Transparency Raises Questions
The blank specific issues field in Genentech's Q2 LDA filing limits external analysis of the company's precise legislative priorities during a period of significant regulatory flux. As CMS advances its negotiation authority and the MFN policy reshapes market dynamics, the pharmaceutical industry's lobbying footprint continues to expand, though the specific contours of its advocacy remain partially obscured.